Artificial Cell Technologies

Artificial Cell Technologies (ACT) is redefining the production of vaccines available globally. This New Haven-based company is actively developing the first patented technology for rapid synthetic vaccine production. Their unique approach enables ACT to produce multivalent vaccines at exponentially faster speeds, with the ability to achieve personalization.